Pipeline
ABL104
HomePipelineABL104
-
- Pipeline
- ABL104
-
- Program Target
- EGFRx4-1BB
-
- Disease Indication
- Solid Tumor
-
- Development Stage
- IND enabling study
- Summary
- ABL104 is a bispecific antibody that simultaneously targets EGFR and 4-1BB, crosslinking and activating 4-1BB signaling only in the presence of EGFR-expressing tumor cells. Additionally, ABL104 induces stronger antitumor activity by blocking EGFR signaling. ABL104 significantly inhibits tumor growth and portects mice from tumor recurrence by inducing tumor-specific immunological memory.
MOA of ABL104
ABL104 in the Grabody™-T BsAb Platform activates T-cells only in the tumor Microenvironment
